16 Apr 2026 Lonza Capsugel to launch UC-FLEX(R) collagen blend for pet food at Interzoo 2026. * Lonza Capsugel is launching UC-FLEX(R) collagen blend, a premium formulation for pet food that combines UC-II(R) undenatured type II collagen with calcium carbonate, to deliver science-backed joint health support for companion animals. * The launch of UC-FLEX(R) bridges the gap between the market demand for pet food to provide functional health benefits and the scientifically validated joint health benefits of UC-II(R) undenatured type II collagen * Attendees at Interzoo can also learn more about the science behind UC-II(R) undenatured type II collagen for pets at booth 7-247 Nuremberg, 16 April 2026 - Lonza Capsugel will be launching its new premium collagen blend for pet food applications at Interzoo 2026 in Nuremberg, 12-15 May. Visitors to booth 7-247 can explore how UC-FLEX(R) collagen blend helps brands stay one step ahead in the pet food market, meeting soaring demand for effective, science-backed joint health support. Consumer research shows that more than 40% of global pet owners are interested in pet food providing functional health benefits such as joint health,[i] and pet food launches containing collagen rose by 34% from 2021 to 2025.[ii] To help brands seize this market opportunity, Lonza Capsugel is launching its UC-FLEX(R) collagen blend formulated specifically for companion animals*, combining UC-II(R) undenatured type II collagen with calcium carbonate** to deliver effective, science-backed support in pet food applications. "This expansion of our UC-II(R) Pets portfolio bridges a crucial gap between the scientifically validated joint health benefits of UC-II(R) undenatured type II collagen and the specific formulation and processing demands of pet food," comments Dr. Zain Saiyed, Global Director, Research & Product Development (Dosage Form Solutions & Ingredients) at Lonza Capsugel. "UC-FLEX(R) collagen blend leverages UC-II(R) science in a form optimized for pet food formulation, enabling brands to deliver premium, trusted joint health support" Attendees can also learn more about the science behind Lonza Capsugel's market-leading UC-II(R) undenatured type II collagen for pets. Backed by more than two decades of research and 10 peer-reviewed research publications in companion animals, UC-II(R) collagen is the most researched brand of undenatured type II collagen on the market.**** Plus, the uniquely low effective dose of just 40 mg/day and formulation flexibility of UC-II(R) Pets mean that it's scientifically validated joint health support can be easily incorporated into numerous convenient applications such as treats or chews.[iii,iv] Visit booth 7-247 at Interzoo 2026 or book a meeting to learn how brands can stay one step ahead with UC-FLEX(R) and Lonza Capsugel: Interzoo 2026 Lonza Capsugel Contact Details Anne Holderbach Director, Strategic Marketing Tel +33 76 267 9876 For Media Inquiries: [email protected] Disclaimer Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third party owners and are used only for informational purposes. i Innova Pet owners survey 2025 ii Innova Market Insights (2025). Joint Health in Pet Industries iii Pates, et al. (2023) UC-II(R) undenatured type II collagen data show retention during functional food and beverage prototype processing. Data in Brief, 48, 109216. [iv] Cabezas, et al. (2022). Long-term supplementation with an undenatured type-II collagen (UC-II(R) formulation in dogs with degenerative joint disease: Exploratory study. Open Vet J, 12(1), 91-98. *Lonza offers UC-II(R) undenatured type II collagen in multiple formats for different applications: UC-II(R) collagen for human dietary supplements, UC-II(R) Halal for human dietary supplements with Halal certification, and UC-II(R) Pets for pet supplement applications. Product availability and specifications may vary by region ** Calcium carbonate added as a carrier to ensure uniform distribution in pet food ***Manufacturing site is included in the TRACES list of approved non-EU establishments (ref. SC-COL-0001) for production of collagen for animal consumption ****As of January 2026

2026 年 4 月 02 日 Stay one step ahead with Lonza Capsugel at Vitafoods Europe 2026. * Lonza Capsugel will showcase its plant-based capsules, European manufacturing capabilities, dosage form solution expertise and health ingredients, alongside inspirational product concepts at Vitafoods Europe 2026, booth #3F72. * The event marks a new chapter for the company following the divestment of its Capsules & Health Ingredients business to Lone Star Funds. * Attendees can hear from Lonza Capsugel's Senior Director of Sustainability, Sofia Sotiropoulou, on leveraging sustainability for brand differentiation and market leadership. Barcelona, Spain, 2 April 2026 - At Vitafoods Europe 2026, booth #3F72, Lonza Capsugel will showcase how nutraceutical brands can stay one step ahead with their next supplement innovation. This year's appearance also comes as the company enters a significant new chapter following the recently signed agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds ('Lone Star'), marking an important milestone for the company as it continues to strengthen its strategic focus. Attendees can explore how the company's high-performing plant-based capsules, European capsule manufacturing capabilities, sustainability credentials, dosage form solutions and health ingredients, alongside inspirational product concepts, can help customers get ahead and stay ahead in the nutraceutical market. At its booth, Lonza Capsugel will invite visitors to explore: * Capsugel(R) Plantcaps(R) capsules: Built for premium oxygen protection that lasts, Capsugel(R) Plantcaps(R) capsules are the only pullulan capsule designed for both powders and liquid fills.* Their superior oxygen barrier helps brand protect their sensitive ingredients, while also aligning with consumer expectations for clean, sustainable products. With a naturally high-luster finish and no risk of "spotting" concerns, Capsugel(R) Plantcaps(R) capsules deliver on performance and visual appeal. * The advantages of Made in Europe capsule manufacturing: With close to 94% of its capsules produced in European sites shipped to European customers, Lonza Capsugel supports local manufacturing and reduced carbon emissions** product claims in Europe, as well as end-to-end traceability, from raw material purchasing to consumers. * Planet-friendly*** capsule solutions: Aligned with the growing number of consumers seeking more sustainable nutraceutical supplements,[i,ii] Lonza Capsugel will highlight how it can help customers drive brand trust and differentiation. Sofia Sotiropoulou, Senior Director of Sustainability and Climate Innovation will present "Sustainability by Design: Partnering to Stay One Step Ahead with Lonza Capsugel." on May 5, from 13:35-14:05 at the Vitafoods Europe Insights Theatre. Sofia will demonstrate how Lonza Capsugel uses sustainability and circularity principles to help customers co-create products with a lower environmental impact and reduced carbon footprint through its Center of Applied Sustainability. Additionally, Sofia will present the latest trends shaping the nutraceutical market and how sustainability can be leveraged to build brand differentiation and innovation via products with science-backed and regulatory compliant sustainability credentials. At its booth, Lonza Capsugel will spotlight its investments in decarbonizing manufacturing, particularly at its European facilities in Bornem (Belgium) and Colmar (France), which as of 2025, run on 100% renewable electricity, reinforcing its goal to produce capsule solutions that make a positive difference for its customers and the planet. * Science-backed joint health and mobility support for humans and pets: Lonza Capsugel's UC-II(R) undenatured type II collagen is clinically shown to improve joint flexibility in healthy adults.[iii,iv,v] What's more, UC-II(R) undenatured type II collagen is available at different grades for both humans and dogs, allowing owners to not only look after their own joint health but also that of their companion animals. UC-II(R) Pets offers joint health and mobility support at a low daily dose of 40 mg.[vi,vii,ix,x] * Dosage form solutions expertise: Through its Innovation Services, Lonza Capsugel's advanced polymer science and capsule technology expertise can help turn complex technical challenges into breakthrough supplements. For instance, its Capsugel(R) Liquid-Filled capsules provide leak prevention for enhanced ingredient protection while its Capsugel(R) Beadlets technology supports tailored release profiles that deliver otherwise incompatible ingredients. Capsugel(R) DUOCAP(R) Dual Release Capsules combine multiple ingredients into one powerful dose, while also protecting acid-sensitive ingredients and enabling tailored release profiles. As formulation complexity rises across Europe, Lonza Capsugel also brings a unique perspective on how CDMO roles are evolving - sharing insights from working closely with leading manufacturers and supporting brand owners navigating growing technical, regulatory, and clean-label demands. * In-stock and ready-to-go program. When product launches need to be fast, so you can stay ahead of the competition, Lonza Capsugel provides fast shipping. Its colorful capsules can be quickly delivered in a variety of polymers, sizes, and quantities that allow for a timely solution for growing customer demands, exciting market dynamics, and high quality, science-backed products.**** In a rapidly changing world, Lonza Capsugel's breadth and depth of expertise, along with a strong perspective on future trends and market dynamics, enables it to anticipate the needs of the industry and provide proactive solutions. Find out more about Lonza Capsugel at Vitafoods Europe 2026, May 5-7. Visitors can book an appointment here to meet with the expert team from Lonza Capsugel at booth #3F72. Lonza Capsugel Contact Details Anne Holderbach Director, Strategic Marketing Tel +33 76 267 9876 For Media Inquiries: [email protected] Disclaimer Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third party owners and are used only for informational purposes. i FMCG Gurus announces their Top Ten Trends for 2025. October 2024. 可查阅于:https://fmcggurus.com/blog/fmcg-gurus-announces-their-top-ten-trends-for-2025/ ii NielsenIQ (2025) The changing story of sustainability. 可查阅于:https://nielseniq.com/global/en/landing-page/tl-the-changing-story-of-sustainability/ iii Schön, C. et al. (2022).UC-II(R) 非变性 II 型胶原蛋白对膝关节灵活性的影响:一项多中心,随机,双盲,安慰剂对照临床研究.《整合与补充医学杂志》,28(6),540-548 [iv] Soucie, J. M., et al. (2011).活动度测量:reference values and a database for comparison studies. Haemophilia, 17(3), 500-507. v Knaub, K. et al. (2022).UC-II(R) 非变性 II 型胶原蛋白可缓解健康受试者的膝关节不适并提升其活动能力:一项随机,双盲,安慰剂对照临床研究.Journal of Clinical Trials, 12(1):1000492. [vi] Varney et al. (2022).Impact of supplemented undenatured type II collagen on pain and mobility in healthy Labrador Retrievers during an exercise regimen. Transl Anim Sci, 6, 1-7. [vii] Varney et al. (2021).Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy dogs during an exercise regimen. Transl Anim Sci, 5, 2. [viii] Gupta et al. (2012).Comparative therapeutic efficacy and safety of type-II collagen, glucosamine and chondroitin in arthritic dogs: Pain evaluation by ground force plate: Arthritis treatment in dogs. J Anim Physiol Nutr, 96, 770-777. ix D'Altilio et al. (2007).Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Toxicol Mech Methods, 17, 189-196. x Peal et al. (2007).Therapeutic efficacy and safety of undenatured type-II collagen alone or in combination with (-)-hydroxycitric acid and ChromeMate in arthritic dogs. J Vet Pharmacol Ther, 30, 275-278. *According to market data in 2026. **Reduced carbon emissions versus global non decarbonized suppliers. Calculation based on product carbon footprint external study, performed in 2024 with 2023 reference data comparing Lonza Capsugel versus weighted average for the rest of market, excluding Lonza. At the time of study, it was assumed that average market was not decarbonized at company level. ***Based on carbon footprint data and transition to renewable electricity. ****Availability, color, and technology offerings vary by region.

Lonza launches Media Development Lab in Singapore for cell culture media optimization. March 25, 2026 * New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and reliability * The offering is designed to improve performance, reduce risk, and help ensure smooth scale-up into manufacturing * The service has been offered at Lonza's Singapore (SG) site since March Basel, Switzerland, 26 March 2026 - Life Science Newswire - Lonza, one of the world's largest contract development and manufacturing organizations (CDMOs), today announced the launch of its Media Development Lab at its Singapore site. The offering aims to support bioprocessing customers in optimizing their media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale-up risk and strengthening long-term supply readiness. As development timelines accelerate and process complexity increases, the cost and risk associated with late-stage reformulation and scale-up continue to rise. Many organizations still lack structured media optimization and alignment between development and manufacturing. To address these challenges, the Media Development Lab provides a systematic approach to early media optimization while accounting for scalability, raw material readiness, and GMP manufacturability. Leveraging Design of Experiments, the service evaluates multiple variables simultaneously to identify key performance drivers, accelerating development timelines, and reducing unnecessary iterations. It combines access to Lonza's proprietary, diverse media and feed libraries with manufacturability insights to identify robust, scalable formulations early in development, with structured outputs that define performance ranges and process robustness. Michael Goetter, Head of Bioscience, Specialized Modalities, Lonza, commented: "We are committed to providing customers with the services they need to reduce early-stage risk and select media formulations that are effective at a laboratory scale and simultaneously practical and reliable in manufacturing. Our new Media Development Lab enables us to support customers at the critical front end of their programs, shape formulation strategy, and create a natural pathway into non-GMP and GMP manufacturing."